✦ LIBER ✦

PND38 Cost Minimization Analysis of Fingolimod Versus Natalizumab in the Second-Line Treatment of Remittent-Recurrent Multiple Sclerosis

✍ Scribed by Crespo, C.; Izquierdo, G.; García-Ruiz, A.; Granell, M.; Brosa, M.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PND33 Cost Minimization Analysis of Fing

✍ B. Verheggen; M. Treur; M. Groot 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Cost minimisation analysis of fingolimod

✍ Crespo, C.; Izquierdo, G.; García-Ruiz, A.; Granell, M.; Brosa, M. 📂 Article 📅 2014 🏛 Elsevier 🌐 English ⚖ 480 KB

Cost-effectiveness of natalizumab versus

✍ O’Day, Ken; Meyer, Kellie; Miller, Ross M.; Agarwal, Sonalee; Franklin, Meg 📂 Article 📅 2011 🏛 Informa plc 🌐 English ⚖ 373 KB

PND23 Economic Evaluation of Natalizumab

✍ S.T. Alexopoulos; B. Deniz; A.R. Walker; R. Arnold; D. Bates 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB

PND30 Cost Analysis of Glatiramer Acetat

✍ Sánchez-de la Rosa, R.; Sabater, E.; Casado, M.A. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

Natalizumab is effective as second line

✍ N. Putzki; K. Kollia; S. Woods; E. Igwe; H. C. Diener; V. Limmroth 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB